25^th International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences September 17-18, 2018 Dubai, UAE

Biography:

Ernesto Delgado Cidranes MD. Ph.D. is a Spanish Anesthesiologist. Director, CEO, and Founder at Advanced Pain & Aesthetic Management Center Madrid. Editorial Board Member of Journal Pain Management and Therapy. USA AIUM Members, Reviewer and Advisor Journal of Ultrasound in Medicine, American Institute (USA), Member of Organizing Committee for World Pain Medicine Conferences. Expert in pain treatment. Chairman Department of Anesthesia and Pain Medicine, Spanish University Health Ministry. International Professor of Advanced Ultrasound. Heat Pain Unit La Milagrosa Hospital & Los Madroños Hospital Madrid Staff of Anesthesiology of Ruber Quirón Hospital Madrid He has an integrative and interdisciplinary concept in the treatment of pain.

Abstract:

Biography:

Abstract:

In recent years several major technical advances particularly in the treatment of brain and spinal tumors, vascular malformations and skull base surgery have been introduced into neurosurgery. These include refinements in microsurgical techniques, microscopic fluorescent techniques (e.g. 5-ALA, ICG-angiography, etc.) for maximal safe resection of intrinsic brain tumors and treatment of aneurysms and AVMs, introduction of neuroendoscopy and routine usage of intra-operative neuromonitoring in appropriate cases. We present these latest technical advances in the field of neurooncology, for the resection of skull base lesions and for the treatment of vascular malformations demonstrating their impact on preserving neurological integrity with resultant preservation of patient’s life quality after micro neurosurgical resection of tumors (e.g. Glioma, meningioma, neurinoma/schwannomas, etc.) treatment of vascular malformations (aneurysm, AVM, cavernoma) and treatment of skull base lesions. Appropriate selection and application of these new techniques under discussion in neurosurgery has resulted in a better outcome after microsurgical treatment of brain and spinal tumors, vascular malformations and skull base lesions. This includes more radical and safer tumor resection with avoidance of new neurological deficits and with preservation of patient’s neurological integrity, prolonged life expectancy in malignant brain tumors and preservation of patient’s life quality after surgery.

Biography:

Sawsan Abuhamdah is a Jordanian Registered Pharmacist. She has completed her PhD from Durham University, UK and Postdoctoral studies from Granada Medical School, Department of Pharmacology, Spain and has won Postdoctoral Fulbright Research Award at the University of Toledo, Department of pharmacology and experimental therapeuticsSawsan Abuhamdah is a Jordanian Registered Pharmacist. She has completed her PhD from Durham University, UK and Postdoctoral studies from Granada Medical School, Department of Pharmacology, Spain and has won Postdoctoral Fulbright Research Award at the University of Toledo, Department of pharmacology and experimental therapeutics, Ohio, USA. She worked as an Associate Professor at the Faculty of Pharmacy, University of Jordan and now is currently working as a Deputy Dean, College of Pharmacy, Al Ain University of Science and Technology, Abu Dhabi, UAE. She has published many research articles in peer-reviewed journals. She is also a Member of the British Pharmacological Society (BPS), British Neuroscience Association (BNA), Sigma Phi Sigma pharmaceutical Sciences Honor Society, University of Toledo, USA, Jordan Pharmaceutical Association. She has been serving as an Editorial Board Member of reputable pharmaceutical journals., Ohio, USA. She worked as an Associate Professor at the Faculty of Pharmacy, University of Jordan and now is currently working as a Deputy Dean, College of Pharmacy, Al Ain University of Science and Technology, Abu Dhabi, UAE. She has published many research articles in peer-reviewed journals. She is also a Member of the British Pharmacological Society (BPS), British Neuroscience Association (BNA), Sigma Phi Sigma pharmaceutical Sciences Honor Society, University of Toledo, USA, Jordan Pharmaceutical Association. She has been serving as an Editorial Board Member of reputable pharmaceutical journals.

Abstract:

Background: Alzheimer's Disease (AD) is a progressive neurodegenerative disease where symptoms appear after significant neuronal loss. Current treatments for AD do not significantly alter the disease process, where they temporarily improve symptoms. In vitro data has indicated that low doses of vanillin reduce beta-amyloid aggregation and may possess cytoprotective effects. This research aims to investigate the effect of vanillin on the AlCl3 mouse model of AD and thus its possible usefulness in managing AD.

Method: Male albino mice were divided into 8 groups of 10. Each group received different treatments of AlCl3, AlCl3+vanillin (30, 60 or 120 mg kgG1 day G1), vanillin alone and control. These experiments lasted for 30 days after which animals were subjected to behavioral and neurochemical assessment. Analysis was carried out using one way analysis of variance (ANOVA) with Dunnett's post-test.

Result: Lower doses of vanillin led to improvements in behavioral and neurochemical deficits induced by AlCl3. Conversely, a high dose of vanillin caused an exaggeration in the behavioral and neurochemical deficits induced by AlCl3. Furthermore, highest dose vanillin treatment, on its own, inflicted behavioral and neurochemical deficits comparable to those caused by AlCl3.

Conclusion: It is concluded that vanillin negatively impacted cholinergic neuronal survival. Any marked benefits with lower doses of vanillin were attributed to its ability to indirectly increase synaptic acetylcholine abundance through blocking its degradation. 

Biography:

Nicandro Figueiredo is a Spinal Neurosurgeon from Brazil. He is currently working at Medcare Orthopedic and Spine Hospital, Dubai. He completed his Bachelors from University of Brasilia (UnB) and his Residency in Neurosurgery in Base Hospital of Brasilia. He also completed his Masters and PhD from the University of Brasilia, Brazil. He was selected for International Fellowship-training in Spinal Surgery in USA, at the Johns Hopkins Hospital, Baltimore and University of Wisconsin, Madison and Post-doctoral Research Fellow in Spinal Surgery in USA at the University of Wisconsin. He is also a Visiting Professor of Neurosurgery and Spinal Surgery in Brazil. He worked as a Consultant Spinal Neurosurgeon for 2 years in Riyadh, KSA, at Dr Sulaiman Al Habib Hospital. He is Board Certified as a Neurosurgeon in Brazil, as a Consultant Neuro-Spinal Surgeon and as a Specialist Spinal Neurosurgeon, Dubai. He is also a member of North American Spine Society, AO SPINE Society (AO-Middle-East), Congress of Neurological Surgeons (CNS-USA), Brazilian Spine Society (BSS), Brazilian Neurosurgical Society (SBN), Brazilian Academy of Neurosurgery (ABNc), Neurosurgical Society of Mato Grosso (vice-president-Brazil), Saudi Association of Neurological Surgery and Pan-Arab Spine Society (PASS). He is also an Academic Editor (Spinal Surgery Section) of the Journal Medicine and has also published many articles.

Abstract:

This systematic review about Intraspinal Ependymoma (ISE), limited to the previously established criteria, was based on 27 papers, including 1,211 patients Unfortunately, there were not many published case series in the last 10 years about spinal ependymoma and even lesser number of series showing separated data of the two subtypes of ependymoma, myxopapillary and cellular ependymoma, although their clinic-pathological behavior are quite different. The overall recurrence/progression rate was 16.29%. The highest incidence of recurrence disease occurred in patients submitted to partial resection plus radiotherapy 66.66% and the lowest 8% after total resection plus radiotherapy. The mean PFS was 65.5 months, 5 years PFS rate was 74.75%, and 10 years PFS rate 69.5%. Regarding studies including only Myxopapillary Ependymoma (MPE), based on 5 papers, 199 patients were included. The overall recurrence/progression rate was 24.12%, higher than for the average of all ependymoma 16.29% and much higher than for cellular 3.63%. Five and 10 years PFS was 68.75% and 62%, respectively. Interestingly, the highest incidence of recurrence disease occurred in patients submitted to subtotal alone and partial resection plus radiotherapy 100%, followed by subtotal plus radiotherapy 34.78%. Gross-total resection alone resulted in 15.21%, while gross-total plus radiotherapy reduced the recurrence rate to 5.26%. The overall 5 years PFS rate 68.75%, being 78.4% for patients submitted to surgery plus radiotherapy and 49.7% for those submitted to surgery only. The 10 years PFS rate 73%, being 75% for patients submitted to surgery plus radiotherapy, and 37% for those submitted to surgery only. A review of series including sufficient data regarding Intramedullary Ependymoma (IME), was based on 4 papers, including 143 patients. The overall recurrence/progression rate was 3.63%. The highest incidence of recurrence occurred in patients submitted to subtotal resection alone 5.26%, followed by gross-total alone 3.37%. This review provides level IV of medical evidence supporting that early diagnosis and better preoperative neurological status can improve the postoperative neurological outcome in patients treated with intraspinal ependymoma. This review provides level IV of medical evidence supporting the role of gross-total resection in the management of intraspinal ependymoma, especially when such a resection can be accomplished without major morbidity. This review provides level IV of medical evidence supporting the role of post-operative radiation therapy as an option to potentially reduce the recurrence/progression of the tumor in patients with intraspinal ependymoma submitted to incomplete resection. This review also provides level IV of medical evidence supporting the role of routine post-operative radiotherapy as an option to potentially reduce the recurrence/progression of the tumor in patients operated for myxopapillary ependymoma, even in patients who underwent gross-total resection. There were some limitations to this work. As a retrospective study, there was selection bias, limited comparable results and there is lack of a standardized way to describe the main results for most of the papers. Experience with patients having intraspinal ependymoma may be limited, even in larger medical centers. Yet, practicing neurosurgeons will encounter patients with those neoplasms and therefore need to be aware of their clinical presentation, diagnostic evaluation, and especially the best management options. Intraspinal ependymoma is not as benign as proposed by its histology, but has a high potential of recurrence and/or progression, about 16% in general, but can be as high as 24% for myxopapillary and as low as 4% for intramedullary ependymoma. Therefore, there is still controversy regarding the best management of those patients. In this broad and recent systematic review, could be noticed that for intraspinal ependymoma, in general, the highest recurrence rate occurred at the groups of patients submitted to incomplete resection, with or without radiotherapy and the lowest in those who underwent gross-total resection, with or without radiation therapy. The routine post-operative radiotherapy should be considered in patients operated for myxopapillary ependymoma, even in patients who underwent gross-total resection.